Bailard Inc. Purchases New Position in Electromed, Inc. (NYSE:ELMD)

Bailard Inc. acquired a new position in shares of Electromed, Inc. (NYSE:ELMD) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 7,597 shares of the company’s stock, valued at approximately $224,000.

A number of other institutional investors also recently made changes to their positions in the company. Navellier & Associates Inc. increased its stake in shares of Electromed by 228.5% during the fourth quarter. Navellier & Associates Inc. now owns 56,368 shares of the company’s stock worth $1,666,000 after purchasing an additional 39,208 shares during the period. Pekin Hardy Strauss Inc. grew its holdings in Electromed by 9.9% in the 3rd quarter. Pekin Hardy Strauss Inc. now owns 38,185 shares of the company’s stock valued at $820,000 after buying an additional 3,435 shares in the last quarter. Bank of New York Mellon Corp increased its position in Electromed by 235.8% during the 4th quarter. Bank of New York Mellon Corp now owns 31,615 shares of the company’s stock worth $934,000 after buying an additional 22,200 shares during the period. Ellsworth Advisors LLC acquired a new stake in shares of Electromed during the fourth quarter worth $734,000. Finally, State Street Corp boosted its position in shares of Electromed by 14.5% in the third quarter. State Street Corp now owns 22,066 shares of the company’s stock valued at $474,000 after acquiring an additional 2,800 shares during the period. Institutional investors own 40.82% of the company’s stock.

Insider Buying and Selling

In related news, Director Kathleen Skarvan sold 38,954 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $29.28, for a total transaction of $1,140,573.12. Following the completion of the sale, the director now directly owns 32,622 shares in the company, valued at $955,172.16. This represents a 54.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Andrew Summers sold 50,751 shares of Electromed stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $27.30, for a total value of $1,385,502.30. Following the completion of the transaction, the director now owns 65,714 shares in the company, valued at approximately $1,793,992.20. This represents a 43.58 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 133,618 shares of company stock valued at $3,821,636 over the last quarter. 14.00% of the stock is owned by company insiders.

Electromed Stock Performance

ELMD opened at $25.98 on Thursday. Electromed, Inc. has a 52-week low of $13.74 and a 52-week high of $35.56. The firm has a market cap of $222.31 million, a P/E ratio of 34.64 and a beta of 0.33. The business’s fifty day moving average is $31.21 and its 200-day moving average is $26.00.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ELMD shares. StockNews.com lowered shares of Electromed from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. B. Riley began coverage on shares of Electromed in a research report on Thursday, February 20th. They issued a “buy” rating and a $38.00 price target for the company.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.